Overview

The Effect of Obesity in Dexmedetomidine Metabolic Clearance

Status:
Unknown status
Trial end date:
2017-12-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to study the effect of obesity in dexmedetomidine pharmacokinetics and pharmacodynamic profile.
Phase:
Phase 4
Accepts Healthy Volunteers?
Accepts Healthy Volunteers
Details
Lead Sponsor:
Pontificia Universidad Catolica de Chile
Treatments:
Dexmedetomidine
Criteria
Inclusion Criteria for obese patients:

- American Society of Anesthesiology classification I-III patients.

- Both genders.

- Age between 18 - 60 years.

- Body mass index higher than 40 Kg/m2.

Inclusion Criteria for non-obese patients:

- American Society of Anesthesiology classification I-II patients

- Both genders.

- Age between 18 - 60 years

- Body mass index lower than 30 Kg/m2.

Exclusion Criteria:

- Known allergy to study drugs

- Uncontrolled hypertension.

- Heart block greater than first degree.

- Chronic hepatic and kidney disease.

- Patients taking any drug acting in the central nervous system within 24 hrs before
surgery.

- Patients taking drugs that induce overexpression of liver cytochrome P450-complex
enzymes (Carbamazepine, Phenytoin, Phenobarbital, Rifampicin, Dexamethasone,
Griseofulvin, Terbinafine, Prednisone, Hydrocortisone, Modafinil).)

- Known addiction to illicit drugs.

- Pregnancy.

- Current or past oncologic disease.